← Eichor
Condition: Alopecia Areata Aa Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Alopecia Areata Aa

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
Phase 1 · 2 location(s) · HCW Biologics · NCT07049328Regeneron AA Multicenter (Dupilumab)
Phase 2 · 3 location(s) · Emma Guttman · NCT05551793CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Phase N/A · 1 location(s) · CorEvitas · NCT05745389Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Phase 4 · 1 location(s) · Erasmus Medical Center · NCT07381556A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan W
Phase 3 · 15 location(s) · AbbVie · NCT07023302Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06573593CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Phase N/A · 1 location(s) · CorEvitas · NCT06562270A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in
Phase 1/Phase 2 · 7 location(s) · Aldena Therapeutics · NCT06826196Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Phase N/A · 81 location(s) · Pfizer · NCT06531109
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.